Aberrant hydroxymethylation in promoter CpG regions of genes related to the cell cycle and apoptosis characterizes advanced chronic myeloid leukemia disease, poor imatinib respondents and poor survival

Table 5 Haematological parameters of CML patients at base line

Characteristics	CML Patients (n = 150)	Imatinib 400-mg OD dose group (n = 59)	Imatinib 600-mg OD dose group (n = 91)
Total Leukocyte Count/mm³ (TLC)
Median	1,42,200	1,54,000	1,25,800
Range	3,460—9,64,000	19,520–9,64,000	3,460–6,73,650
Hemoglobin (gm/dL)
Median	9.3	9	9.8
Range	4.7–17.2	4.7–13.4	5–17.2
Platelets (Lacs/mm³)
Median	2.95	2.29	3.75
Range	1.78–15.11	1.79–2.97	1.78–15.11

ISSN: 1471-2407